Ignite Creation Date:
2025-12-24 @ 9:45 PM
Ignite Modification Date:
2026-01-01 @ 5:22 PM
Study NCT ID:
NCT00098332
Status:
COMPLETED
Last Update Posted:
2013-07-10
First Post:
2004-12-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
Sponsor:
BioCryst Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-11
Start Date Type:
None
Primary Completion Date:
2010-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-07
Completion Date Type:
ACTUAL
First Submit Date:
2004-12-07
First Submit QC Date:
None
Study First Post Date:
2004-12-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-07-09
Last Update Post Date:
2013-07-10
Last Update Post Date Type:
ESTIMATED